Compare Recursion Pharmaceuticals Inc (RXRX) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while State Street Technology Select Sector SPDR ETF trades at $180.68. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLK | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $198.21 |
52-Week Low | $2.84 | $127.49 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
XLK trades at $175.71 with minimal daily movement (+0.07%), showing technical bearish signals while maintaining strong year-to-date performance of 33%. The ETF's technical indicators show selling pressure with bearish moving averages, though oscillators remain neutral. Recent news highlights XLK as the top-performing sector SPDR in 2026, driven by technology sector strength and institutional inflows.
Outlook remains positive given technology sector momentum and strong earnings expectations, though concentration risk and technical weakness warrant monitoring. The ETF benefits from sector leadership but faces headwinds from potential Fed policy shifts and market volatility. Current levels near pivot point resistance at $176 suggest near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
